Skip to content

CA-125

Also called Cancer Antigen 125

A protein elevated in many ovarian cancers, used mainly to monitor known disease and evaluate suspicious pelvic masses.

  • Forwomen
  • Lab price$35.00
  • RetestPer gynecologist

What your result means

Not a screening test for the general population — it produces too many false positives from benign gynecological conditions.

Ranges
Standard (women)
<35 U/mL
Optimal (women)
Low. Interpret only with clinical context and imaging.

Tumor markerOnly interpretable in clinical context. Never a self-check.

Order it yourself

One test, drawn at a Quest lab near you. The price is the lab’s, from Marek’s own menu.

CA-125 test
Marek Diagnostics · single test, drawn at Quest
$35.00
Code CAMERON
Order this test

Code CAMERON takes 10% off. Marek’s checkout adds its one-time blood-draw fee to individual tests and shows the total before you pay.

Order it with CEA (Carcinoembryonic Antigen) (2 tests, one cart)

What moves CA-125

Elevated: ovarian cancer, but also endometriosis, fibroids, pelvic inflammatory disease, menstruation, pregnancy, and benign cysts — all far more common.

If it’s high: Requires gynecological evaluation with imaging.

If it’s low: Reassuring but doesn't exclude disease.

No peptide application.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Everything else about CA-125

What your CA-125 result means

Each possible result, and what to do next

What was your CA-125 result?

Within reference range
Does not exclude ovarian cancer — CA-125 is normal in roughly half of early-stage disease, which is precisely why it fails as a screening test.
Mildly raised
Extremely common for benign reasons: endometriosis, fibroids, ovarian cysts, pelvic inflammatory disease, menstruation, pregnancy and liver disease all raise it. In a premenopausal woman a mild elevation is usually benign.
Substantially raised
Requires prompt clinical assessment, particularly in a postmenopausal woman, where the benign explanations are fewer. It is interpreted alongside imaging rather than alone.

What to do next. See a doctor with this result. CA-125 is not recommended as a screening test in average-risk women for the reasons above, and a raised value on its own diagnoses nothing. If it was ordered because of symptoms — bloating, early satiety, pelvic pain, urinary urgency that is persistent and new — those symptoms are the thing to pursue.

What can skew the result

2 things can change the reading or the real level

Some change your real level; others only change the reading. Each one says which, and what to do about it.

Menstrual cycle phaseTiming

Varies severalfold across a normal cycle, so a result without a cycle day attached is close to uninterpretable.

Do this: Note the cycle day. Day 3 for the follicular baseline; seven days after ovulation for the luteal phase.

The value is real but reflects a moment — retime it
Endometriosis, fibroids, pregnancy, peritoneal irritationPhysiological state

CA-125 rises with a long list of benign conditions. Its specificity in pre-menopausal women is poor, which is why it is not a screening test.

Do this: Not a screening test in the general population. Interpret only in context and with imaging.

A real change — retest once it passes

Plan of attack

What to do, in this order
  1. Confirm the number is real

    Menstrual cycle phase. Varies severalfold across a normal cycle, so a result without a cycle day attached is close to uninterpretable. Note the cycle day. Day 3 for the follicular baseline; seven days after ovulation for the luteal phase.

  2. Read it with its partner

    Know the symptoms instead: persistent bloating, pelvic pain, early satiety and urinary urgency lasting more than a few weeks warrant evaluation. Draw it alongside: CEA (Carcinoembryonic Antigen).

  3. Work out which direction is yours

    If it's high — Requires gynecological evaluation with imaging. Mild elevation in a premenopausal woman is frequently benign.
    If it's low — Reassuring but doesn't exclude disease.

  4. Fix it in order: food, then cause, then everything else

    Nutrition. No specific dietary lever.
    Lifestyle. Attend recommended gynecological screening — cervical screening detects a different cancer, and there is currently no effective population screening test for ovarian cancer, which is precisely why symptoms matter.

  5. Retest

    Per gynecologist. Change one thing at a time, or the retest can't tell you which thing worked.

What a proper work-up looks like

Ask for this, by name
First, check when in your cycle it was drawn. CA-125 rises during menstruation and in early pregnancy, so a raised result taken on day 2 of a period is a different piece of information from the same number mid-cycle. If nobody asked, that is the first thing to establish and it is often the whole explanation. A transvaginal ultrasound is the test that actually answers the question. CA-125 describes a number; imaging describes the ovary. Where a mass is found, the calculation that guides referral is the Risk of Malignancy Index — CA-125 combined with the ultrasound findings and menopausal status.
What it looks like if it’s real
In a premenopausal woman, a mildly raised CA-125 with a normal ultrasound is common and usually benign — endometriosis, fibroids, a cyst or simple cycle timing. It is the combination that means something; the single number does not.
If you are told it is normal
Outside monitoring known disease and screening high-risk (BRCA) women under specialist guidance, this test produces far more false alarms than findings — which is why no guideline recommends it as a general screen, and why finding it on a "comprehensive" wellness panel is a reason for caution rather than reassurance. If yours is mildly raised and you are being watched, ask what the plan actually is. A single value matters far less than the trend — a stable mild elevation with normal imaging behaves very differently from one climbing across draws, and knowing which you are being followed for is the difference between reassurance and months of unfocused anxiety.
The question to ask
“Is this being followed for a trend, and at what point would the plan change?”

Where the optimal range comes from

Not a range — a result category

Not a range — a result category. Positive or negative, a titre, a genotype. The useful content is what each answer means and what to do next.

Measured in
Asymptomatic women — the population in which people most often order this test on their own.
Anchored to
The USPSTF recommends against screening for ovarian cancer in asymptomatic women — Grade D, 2018, concluding with moderate certainty that the harms outweigh the benefits. Reported false-positive rates ranged from 4.2% to 44.2%; between 0.2% and 3.25% of screened women had surgery for a false positive, and up to 15% of those had major surgical complications.
Source
US Preventive Services Task Force, Ovarian Cancer: Screening, 2018.

That harms chain is the answer to 'what is the optimal CA-125'. There isn't one, because in a woman without symptoms the test's most likely effect is a false alarm, and its most likely serious effect is an operation she did not need. CA-125 rises in endometriosis, fibroids, pregnancy, menstruation, pelvic inflammatory disease, liver disease, heart failure and any peritoneal irritation. It has real roles — characterizing a known adnexal mass, and monitoring treated disease — and both of those sit with a specialist who has the imaging in front of them.

What CA-125 measures

And why people check it

What it tells you

A protein elevated in many ovarian cancers, used mainly to monitor known disease and evaluate suspicious pelvic masses.

Why people check it

Not a screening test for the general population — it produces too many false positives from benign gynecological conditions. It has a genuine role in monitoring and in high-risk women (BRCA carriers) under specialist guidance.

What CA-125 means next to other markers

1 pattern worth knowing
A mildly raised tumor marker in a well person

CA-125, CEA, CA 19-9 or calcitonin mildly raised · no symptoms

Tumor markers are monitoring tools, not screening tests, and every one of them rises in benign conditions. CA-125 with endometriosis, fibroids or any peritoneal irritation. CEA with smoking. CA 19-9 with gallstones and any biliary obstruction. Calcitonin with chronic PPI use and kidney impairment.

Interpret only in context, and never as a screen. The trend across serial measurements matters far more than one value.

Panels that carry CA-125

2 panels, prices with code CAMERON

Read it alongside

Related markers, goals and what moves it in the library

The deep read, with sources

What the CA-125 test actually measures, and the references

What CA-125 actually measures — the analyte, and the assay

Read this only if a CA-125 result already exists. Nothing here is an argument for obtaining one, and this site does not route anybody toward it. In a woman with no symptoms the number produces alarms far more often than it produces findings, and an alarm here is answered with a scan and sometimes an operation. What follows is how to read a figure somebody is already holding.

CA-125 is not a protein; it is an epitope on one. The molecule is MUC16, an enormous membrane-tethered mucin whose extracellular domain carries repeated regions bearing the antigenic determinant the original OC125 antibody recognized. The ectodomain is cleaved and shed into circulation, so the assay measures shedding as much as expression Moss 2005.

MUC16 is made by normal tissue, and that is the whole specificity problem. Coelomic-derived epithelium expresses it: peritoneum, pleura, pericardium, endometrium and the fallopian tube. Anything that irritates those surfaces releases it, which is why the list of benign causes is long and common Moss 2005.

The assay is a two-site immunoassay and the two sites are not the same between platforms. First-generation assays used OC125 for both capture and detection; second-generation assays pair OC125 with M11 against a different epitope, and values are not interchangeable. Tumor marker harmonization across external quality assessment programs remains incomplete Sturgeon 2016 van Rossum 2024.

CA-125: what changes the blood, and what only changes the reading

What changes the CA-125 in you:

  1. Menstruation and the menstrual cycle, across which it varies in premenopausal women — the endometrium is a source Moss 2005.
  2. Endometriosis and adenomyosis, which raise it substantially and are far more common than the malignancy the test is associated with.
  3. Pregnancy, particularly the first trimester.
  4. Any peritoneal irritation: pelvic inflammatory disease, recent abdominal or pelvic surgery, ascites of any cause, diverticulitis.
  5. Pleural and pericardial disease, heart failure, and cirrhosis with ascites, all of which raise it through serosal surfaces rather than through anything gynecological.
  6. Epithelial ovarian cancer, which is what the assay was developed for and which raises it in most but not all cases Moss 2005.

What changes the number without changing you:

  1. Heterophilic antibodies. Human sera containing them cause falsely increased CA-125, demonstrated in the immunofluorometric assay as far back as 1990 Boerman 1990.
  2. Human anti-mouse antibodies specifically, which bridge the murine capture and detection antibodies in a sandwich format and produce a false elevation Bertholf 2002. Anybody who has received a murine monoclonal antibody, and a proportion of people who never have, carries them.
  3. The consequences of that, which are not abstract. A paper titled for the consequences of a falsely elevated CA 125 exists because the false result leads to imaging, laparotomy and, in reported cases, surgery on a normal ovary Watt 1994.
  4. Which platform and which antibody pair, since values from different assays are not comparable Sturgeon 2016 van Rossum 2024.
  5. Where in the cycle the sample was drawn, in a premenopausal woman Moss 2005.

Reference interval or decision threshold — which kind of number CA-125 is

The 35 U/mL figure is a historical cut-off, not a reference interval, and it was chosen for a different question. It was set so that roughly 99% of a healthy reference population fell below it — a specificity choice, made before the test was ever proposed for screening.

Applied to a population, that specificity is not nearly enough. Epithelial ovarian cancer is uncommon, so even a small false-positive rate generates far more false alarms than cancers, and each alarm leads to imaging and often to surgery Watt 1994.

The trial that settled the screening question is the reason this page exists in this form. UKCTOCS randomized more than 200,000 postmenopausal women to multimodal screening with a longitudinal CA-125 algorithm, to ultrasound screening, or to no screening, and after long-term follow-up reported no significant reduction in ovarian and tubal cancer deaths Menon 2021. The health technology assessment set out the mortality impact alongside the risks and the harms Menon 2023.

Where CA-125 does have a defined role, it is in women who already have a diagnosis or a mass. Serial values after treatment for known ovarian cancer, and the interpretation of an adnexal mass alongside imaging and menopausal status, are established uses Moss 2005. A number in isolation, in a well woman, is not one of them.

How you would know your CA-125 was wrong — and when to redraw

If a first value is mildly raised, the informative move is usually to wait and repeat rather than to image immediately. CA-125 has a circulating half-life of roughly 5 days, so a value raised by menstruation, a recent operation or a transient peritoneal process falls back over 2 to 6 weeks.

In a premenopausal woman, repeat at a defined point in the cycle — the follicular phase — and compare like with like. A value drawn during menstruation and one drawn mid-cycle are not the same measurement Moss 2005.

Conditions that must match: the same laboratory and the same antibody pair Sturgeon 2016; the same cycle phase; and no recent abdominal or pelvic surgery.

What would have to change for a second value to mean something:

  • Result mildly raised and falling on repeat? That trajectory is characteristic of a benign transient cause, and it is the commonest outcome Moss 2005.
  • Result raised and rising across two or three samples? Rate of change carries more information than any single value — which is the principle the UKCTOCS multimodal algorithm was built on, even though the trial found it did not reduce mortality Menon 2021.
  • Result implausible for the clinical picture? Ask the laboratory to re-run with a heterophile blocking reagent or on a different platform before any imaging is arranged Boerman 1990 Bertholf 2002.
  • Raised with ascites, heart failure or liver disease? Serosal surfaces are the source; the tests that matter are the CMP albumin and liver enzymes and a CBC, not another tumor marker.
  • Raised with cyclical pelvic pain? Endometriosis raises it, and imaging rather than serology is what characterizes that.

What CA-125 cannot tell you

It cannot be used to screen, and the largest randomized trial ever run on the question is the reason. UKCTOCS found no significant mortality reduction from screening, and the accompanying assessment quantified the harms alongside it Menon 2021 Menon 2023.

It cannot localize. The antigen comes from any coelomic-derived epithelium, so a raised value names no organ Moss 2005.

It cannot exclude ovarian cancer. A substantial minority of epithelial ovarian cancers, and most early-stage ones, do not raise it — and mucinous tumors frequently do not Moss 2005.

It cannot be trusted against a discordant clinical picture without excluding interference, because the false-positive mechanism is well documented and its consequences are surgical Boerman 1990 Bertholf 2002 Watt 1994.

It cannot be compared between laboratories, since tumor marker harmonization is incomplete Sturgeon 2016 van Rossum 2024.

The wrong inference people actually draw is that a number under 35 is reassurance and a number over 35 is a diagnosis. Neither holds: the cut-off was a specificity choice made for a different purpose, the commonest causes of exceeding it are benign, and a population trial of over 200,000 women found that acting on the number did not save lives Menon 2021 Moss 2005.

Sources read for these sections

  • Menon U, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021 · PMID 33991479
  • Menon U, et al. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health Technology Assessment 2023 · PMID 37183782
  • Boerman OC, et al. Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clinical Chemistry 1990 · PMID 2357827
  • Bertholf RL, et al. False elevation of serum CA-125 level caused by human anti-mouse antibodies. Annals of Clinical and Laboratory Science 2002 · PMID 12458896
  • Watt PD, et al. Consequences of a falsely elevated CA 125. Clinical Biochemistry 1994 · PMID 7867221
  • Moss EL, et al. The role of CA125 in clinical practice. Journal of Clinical Pathology 2005 · PMID 15735166
  • Sturgeon C, et al. Standardization of tumor markers - priorities identified through external quality assessment. Scandinavian Journal of Clinical and Laboratory Investigation Supplement 2016 · PMID 27542005
  • van Rossum HH, et al. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study. Clinical Chemistry 2024 · PMID 38385453

CA-125 questions

5 answered
What is a normal CA-125 level?
<35 U/mL. Ranges vary by laboratory and assay; always compare to the range printed on your own report.
What is the optimal CA-125 level?
Low. Interpret only with clinical context and imaging. US Preventive Services Task Force, Ovarian Cancer: Screening, 2018.
What does an abnormal CA-125 result mean?
Requires gynecological evaluation with imaging. Mild elevation in a premenopausal woman is frequently benign.
How often should I retest CA-125?
Per gynecologist.
How do I test CA-125?
Through Marek Diagnostics without a doctor's visit, drawn at a Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically through the links on this page.

Sources: ACOG and NCCN guidance — CA-125 is not recommended for ovarian cancer screening in average-risk women.

Inside Skool · $10/mo

The Longevity Baseline protocol is a lesson in Skool

This page tells you what the number means and the order to act in. Skool is where it becomes a plan for your situation, read against your own labs.

  • The full Longevity Baseline protocol, step by step
  • Supplement form, timing and how long to run it
  • The hormones and compounds that move it, and what to watch
Join Skool $10/moCancel anytime

5.0 (15 reviews)1,500+ members

Coach Cam's community on Skool: the public page, with the rating, members and price

Want it built around you?

Educational and research purposes only. Not medical advice; talk to your clinician about results. Lab ranges vary by assay and laboratory: compare against the range printed on your own report. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer and affiliate disclosure

Order this testJoin Skool